475 related articles for article (PubMed ID: 35745875)
21. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression.
Vaupel P; Schmidberger H; Mayer A
Int J Radiat Biol; 2019 Jul; 95(7):912-919. PubMed ID: 30822194
[TBL] [Abstract][Full Text] [Related]
22. Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression.
Yang E; Wang X; Gong Z; Yu M; Wu H; Zhang D
Signal Transduct Target Ther; 2020 Oct; 5(1):242. PubMed ID: 33077737
[TBL] [Abstract][Full Text] [Related]
23. Targeting Metabolic Pathways in Kidney Cancer: Rationale and Therapeutic Opportunities.
Hoerner CR; Miao SY; Hsieh JJ; Fan AC
Cancer J; 2020; 26(5):407-418. PubMed ID: 32947309
[TBL] [Abstract][Full Text] [Related]
24. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.
Chouaib S; Noman MZ; Kosmatopoulos K; Curran MA
Oncogene; 2017 Jan; 36(4):439-445. PubMed ID: 27345407
[TBL] [Abstract][Full Text] [Related]
25. Metabolic reprogramming due to hypoxia in pancreatic cancer: Implications for tumor formation, immunity, and more.
Hao X; Ren Y; Feng M; Wang Q; Wang Y
Biomed Pharmacother; 2021 Sep; 141():111798. PubMed ID: 34120068
[TBL] [Abstract][Full Text] [Related]
26. Targeting metabolic reprogramming in chronic lymphocytic leukemia.
Nie Y; Yun X; Zhang Y; Wang X
Exp Hematol Oncol; 2022 Jun; 11(1):39. PubMed ID: 35761419
[TBL] [Abstract][Full Text] [Related]
27. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α.
Faubert B; Vincent EE; Griss T; Samborska B; Izreig S; Svensson RU; Mamer OA; Avizonis D; Shackelford DB; Shaw RJ; Jones RG
Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2554-9. PubMed ID: 24550282
[TBL] [Abstract][Full Text] [Related]
28. Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies.
Xu R; Yang J; Ren B; Wang H; Yang G; Chen Y; You L; Zhao Y
Front Oncol; 2020; 10():572722. PubMed ID: 33117704
[TBL] [Abstract][Full Text] [Related]
29. Feedback loop between hypoxia and energy metabolic reprogramming aggravates the radioresistance of cancer cells.
Shi Z; Hu C; Zheng X; Sun C; Li Q
Exp Hematol Oncol; 2024 May; 13(1):55. PubMed ID: 38778409
[TBL] [Abstract][Full Text] [Related]
30. Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy.
Bahrambeigi S; Molaparast M; Sohrabi F; Seifi L; Faraji A; Fani S; Shafiei-Irannejad V
Immunol Lett; 2020 Apr; 220():32-37. PubMed ID: 31982460
[TBL] [Abstract][Full Text] [Related]
31. New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment.
Sung JY; Cheong JH
Cells; 2022 Feb; 11(5):. PubMed ID: 35269390
[TBL] [Abstract][Full Text] [Related]
32. The Crosstalk Between Signaling Pathways and Cancer Metabolism in Colorectal Cancer.
Hon KW; Zainal Abidin SA; Othman I; Naidu R
Front Pharmacol; 2021; 12():768861. PubMed ID: 34887764
[TBL] [Abstract][Full Text] [Related]
33. Insights into the Regulatory Role of Non-coding RNAs in Cancer Metabolism.
Beltrán-Anaya FO; Cedro-Tanda A; Hidalgo-Miranda A; Romero-Cordoba SL
Front Physiol; 2016; 7():342. PubMed ID: 27551267
[TBL] [Abstract][Full Text] [Related]
34. Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment.
Wei J; Hu M; Du H
Front Immunol; 2022; 13():845923. PubMed ID: 35281061
[TBL] [Abstract][Full Text] [Related]
35. mTORC2 in the center of cancer metabolic reprogramming.
Masui K; Cavenee WK; Mischel PS
Trends Endocrinol Metab; 2014 Jul; 25(7):364-73. PubMed ID: 24856037
[TBL] [Abstract][Full Text] [Related]
36. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
Bahrambeigi S; Shafiei-Irannejad V
Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
[TBL] [Abstract][Full Text] [Related]
37. [Lipid Metabolic Reprogramming and Metabolic Stress in Liver Cancer].
Xu Z; Yuan KF
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 52(4):561-565. PubMed ID: 34323031
[TBL] [Abstract][Full Text] [Related]
38. mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.
Mafi S; Mansoori B; Taeb S; Sadeghi H; Abbasi R; Cho WC; Rostamzadeh D
Front Immunol; 2021; 12():774103. PubMed ID: 35250965
[TBL] [Abstract][Full Text] [Related]
39. Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer.
Chetta P; Zadra G
Cancer Drug Resist; 2021; 4(1):143-162. PubMed ID: 35582011
[TBL] [Abstract][Full Text] [Related]
40. Modulation of Mitochondrial Metabolic Reprogramming and Oxidative Stress to Overcome Chemoresistance in Cancer.
Avolio R; Matassa DS; Criscuolo D; Landriscina M; Esposito F
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31947673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
